Literature DB >> 348261

Bromocriptine in Parkinsonism.

I Pearce, J M Pearce.   

Abstract

A review of the effects of using bromocriptine in Parkinson's disease showed that it rarely helps patients not primarily improved by levodopa. Patients who show late failure with levadopa and whose response to treatment is declining are helped by combining the two drugs. High cost and severe psychosis are the main disadvantages of bromocriptine, and, although it is not recommended for patients who are doing well on levodopa, it is the best available drug for hospital use in patients who show late failure with levodopa.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 348261      PMCID: PMC1604749          DOI: 10.1136/bmj.1.6124.1402

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  12 in total

1.  Bromocriptine.

Authors:  A J Lees
Journal:  Br J Hosp Med       Date:  1977-10

2.  Comparison of the effects of bromocriptine and levodopa in Parkinson's disease.

Authors:  R B Godwin-Austen; N J Smith
Journal:  J Neurol Neurosurg Psychiatry       Date:  1977-05       Impact factor: 10.154

3.  Sustained levodopa therapy in parkinsonism.

Authors:  K R Hunter; K M Shaw; D R Laurence; G M Stern
Journal:  Lancet       Date:  1973-10-27       Impact factor: 79.321

4.  Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa.

Authors:  J D Parkes; A G Debono; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1976-11       Impact factor: 10.154

5.  On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients.

Authors:  I Shoulson; G A Glaubiger; T N Chase
Journal:  Neurology       Date:  1975-12       Impact factor: 9.910

6.  Letter: Parkinsonism and dementia: effects of levodopa.

Authors:  J Pearce; I Pearce
Journal:  Lancet       Date:  1975-05-31       Impact factor: 79.321

Review 7.  Current concepts of Parkinsonism.

Authors:  J Pearce; I Pearce
Journal:  Postgrad Med J       Date:  1971-12       Impact factor: 2.401

8.  Bromocriptine and levodopa (with or without carbidopa) in parkinsonism.

Authors:  R Kartzinel; P TEYCHENNE; M M Gillespie; M Perlow; A C Gielen; D A Sadowsky; D B Calne
Journal:  Lancet       Date:  1976-08-07       Impact factor: 79.321

9.  Bromocriptine therapy in acromegaly.

Authors:  Y Sachdev; A Gomez-Pan; W M Tunbridge; A Duns; D R Weightman; R Hall; S K Goolamali
Journal:  Lancet       Date:  1975-12-13       Impact factor: 79.321

10.  Treatment of parkinson's disease with bromocriptine.

Authors:  A Lieberman; M Kupersmith; E Estey; M Goldstein
Journal:  N Engl J Med       Date:  1976-12-16       Impact factor: 91.245

View more
  10 in total

Review 1.  Aetiology and natural history of Parkinson's disease.

Authors:  J M Pearce
Journal:  Br Med J       Date:  1978-12-16

2.  Dopamine agonists for negative symptoms in schizophrenia.

Authors:  D J King
Journal:  Br J Clin Pharmacol       Date:  1978-12       Impact factor: 4.335

3.  Low-dose bromocriptine in Parkinson's disease.

Authors:  I Pearce; J M Pearce
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-04       Impact factor: 10.154

4.  Gas-liquid chromatographic analysis of synovial fluid: volatile short-chain fatty acids in septic arthritis.

Authors:  D G Borenstein; C A Gibbs; R P Jacobs
Journal:  Ann Rheum Dis       Date:  1983-08       Impact factor: 19.103

5.  Fate and disposition of bromocriptine in animals and man. II: Absorption, elimination and metabolism.

Authors:  G Maurer; E Schreier; S Delaborde; R Nufer; A P Shukla
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983       Impact factor: 2.441

6.  Adjuvant treatment of Parkinson's disease with dopamine agonists: open trial with bromocriptine and CU 32-085.

Authors:  K Jellinger
Journal:  J Neurol       Date:  1982       Impact factor: 4.849

7.  Long-term experience with bromocriptine in advanced parkinsonism. Results after one year's treatment.

Authors:  E Schneider; P A Fischer
Journal:  J Neurol       Date:  1982       Impact factor: 4.849

8.  Bromocriptine concentration in saliva plasma after long-term treatment of patients with Parkinson's disease.

Authors:  M L Friis; T Johnsen; N E Larsen; E F Hvidberg; H Pakkenberg
Journal:  Eur J Clin Pharmacol       Date:  1980-08       Impact factor: 2.953

9.  Pharmacokinetics of bromocriptine during continuous oral treatment of Parkinson's disease.

Authors:  M L Friis; U Grøn; N E Larsen; H Pakkenberg; E F Hvidberg
Journal:  Eur J Clin Pharmacol       Date:  1979-05-21       Impact factor: 2.953

10.  Bromocriptine in Parkinson's disease: a double-blind study comparing "low-slow" and "high-fast" introductory dosage regimens in de novo patients. UK Bromocriptine Research Group.

Authors: 
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-01       Impact factor: 10.154

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.